BACKGROUND: Non-motor symptoms are very common among patients with Parkinson's disease since the earliest stage, but little is known about their progression and their relationship with dopaminergic replacement therapy. METHODS: We studied non-motor symptoms before and after 2 years from dopaminergic therapy introduction in ninety-one newly diagnosed previously untreated PD patients. RESULTS: At baseline, nearly all patients (97.8%) referred at least one non-motor symptom. At follow-up, only few non-motor symptoms significantly changed. Particularly, depression and concentration became less frequent, while weight change significantly increased after introduction of dopamine agonists. CONCLUSIONS: We reported for the first time a 2-year prospective study on non-motor symptoms before and after starting therapy in newly diagnosed PD patients. Even if non-motor symptoms are very frequent in early stage, they tend to remain stable during the early phase of disease, being only few non-motor symptoms affected from dopaminergic therapy and, specifically, by the use of dopamine agonists.
BACKGROUND: Non-motor symptoms are very common among patients with Parkinson's disease since the earliest stage, but little is known about their progression and their relationship with dopaminergic replacement therapy. METHODS: We studied non-motor symptoms before and after 2 years from dopaminergic therapy introduction in ninety-one newly diagnosed previously untreated PDpatients. RESULTS: At baseline, nearly all patients (97.8%) referred at least one non-motor symptom. At follow-up, only few non-motor symptoms significantly changed. Particularly, depression and concentration became less frequent, while weight change significantly increased after introduction of dopamine agonists. CONCLUSIONS: We reported for the first time a 2-year prospective study on non-motor symptoms before and after starting therapy in newly diagnosed PDpatients. Even if non-motor symptoms are very frequent in early stage, they tend to remain stable during the early phase of disease, being only few non-motor symptoms affected from dopaminergic therapy and, specifically, by the use of dopamine agonists.
Authors: Anna De Rosa; Claudia Carducci; Carla Carducci; Silvio Peluso; Maria Lieto; Andrea Mazzella; Francesco Saccà; Vincenzo Brescia Morra; Sabina Pappatà; Vincenzo Leuzzi; Giuseppe De Michele Journal: J Neurol Date: 2014-09-03 Impact factor: 4.849
Authors: Brit Mollenhauer; Johannes Zimmermann; Friederike Sixel-Döring; Niels K Focke; Tamara Wicke; Jens Ebentheuer; Martina Schaumburg; Elisabeth Lang; Ellen Trautmann; Henrik Zetterberg; Peggy Taylor; Tim Friede; Claudia Trenkwalder Journal: Neurology Date: 2016-05-06 Impact factor: 9.910
Authors: Rui Liu; David M Umbach; Shyamal D Peddada; Zongli Xu; Alexander I Tröster; Xuemei Huang; Honglei Chen Journal: Neurology Date: 2015-04-29 Impact factor: 9.910
Authors: Tanya Simuni; Chelsea Caspell-Garcia; Christopher Coffey; Lama M Chahine; Shirley Lasch; Wolfgang H Oertel; Geert Mayer; Birgit Högl; Ron Postuma; Aleksandar Videnovic; Amy Willis Amara; Ken Marek Journal: Mov Disord Date: 2015-06-11 Impact factor: 10.338
Authors: Marina Picillo; Marianna Amboni; Roberto Erro; Katia Longo; Carmine Vitale; Marcello Moccia; Angela Pierro; Gabriella Santangelo; Anna De Rosa; Giuseppe De Michele; Lucio Santoro; Giuseppe Orefice; Paolo Barone; Maria Teresa Pellecchia Journal: J Neurol Date: 2013-08-30 Impact factor: 4.849